Brief: Medivir's Partner Tango Therapeutics Received FDA Clearance To Start The TNG348 Phase 1/2 Clinical Study

Medivir AB

11/09/2023 10:56

Sept 11 (Reuters) - Medivir AB  MEDIVIR.ST :
    * MEDIVIR'S PARTNER TANGO THERAPEUTICS RECEIVED FDA
CLEARANCE TO
START THE TNG348 PHASE 1/2 CLINICAL STUDY

Source text for Eikon:  ID:nPn5J4F1ma 
Further company coverage:  MEDIVIR.ST 

 ((Reuters.Brief@thomsonreuters.com;))